Mariangela Figini

List of Publications by Year
in descending order

67 papers	2,652 citations	218677 26 h-index	189892 50 g-index
69 all docs	69 docs citations	69 times ranked	4128 citing authors

#	Article	IF	Citations
1	COVID-19 Vaccination in Health Care Workers in Italy: A Literature Review and a Report from a Comprehensive Cancer Center. Vaccines, 2022, 10, 734.	4.4	0
2	Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells. Journal of Experimental and Clinical Cancer Research, 2021, 40, 5.	8.6	9
3	SARS-CoV-2 Serology Monitoring of a Cancer Center Staff in the Pandemic Most Infected Italian Region. Cancers, 2021, 13, 1035.	3.7	2
4	Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. , 2021, 9, e002140.		10
5	Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain. Cancers, 2021, 13, 4081.	3.7	5
6	Validity of Anti-PSMA ScFvD2B as a Theranostic Tool: A Narrative-Focused Review. Biomedicines, 2021, 9, 1870.	3.2	4
7	Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody. Cells, 2020, 9, 2231.	4.1	8
8	Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 154, 246-258.	4.3	20
9	IgE Activates Monocytes from Cancer Patients to Acquire a Pro-Inflammatory Phenotype. Cancers, 2020, 12, 3376.	3.7	15
10	Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs). Scientific Reports, 2020, 10, 8869.	3.3	11
11	Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen. Scientific Reports, 2020, 10, 9313.	3.3	11
12	Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle. Journal of Experimental and Clinical Cancer Research, 2019, 38, 326.	8.6	15
13	A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy. Frontiers in Immunology, 2019, 10, 2514.	4.8	7
14	Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases. Journal of Experimental and Clinical Cancer Research, 2019, 38, 125.	8.6	72
15	An immunologically relevant rodent model demonstrates safety of therapy using a tumourâ€specific IgE. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2328-2341.	5.7	24
16	Selective targeting and degradation of doxorubicin-loaded folate-functionalized DNA nanocages. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1181-1190.	3.3	59
17	Anti-Folate Receptor Alphaâ€"Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer. Clinical Cancer Research, 2018, 24, 5098-5111.	7.0	65
18	Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells. Frontiers in Immunology, 2018, 9, 493.	4.8	14

#	Article	IF	Citations
19	Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. MAbs, 2018, 10, 1084-1097.	5.2	17
20	Anti-Folate Receptor-Î± IgE but not IgG Recruits Macrophages to Attack Tumors via TNFÎ±/MCP-1 Signaling. Cancer Research, 2017, 77, 1127-1141.	0.9	58
21	Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields. Frontiers in Immunology, 2017, 8, 1112.	4.8	17
22	Deregulated MicroRNA-21 Expression in Monocytes from HIV-Infected Patients Contributes to Elevated IP-10 Secretion in HIV Infection. Frontiers in Immunology, 2017, 8, 1122.	4.8	16
23	Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging. Oncotarget, 2017, 8, 10919-10930.	1.8	17
24	Targeting folate receptor alpha for cancer treatment. Oncotarget, 2016, 7, 52553-52574.	1.8	308
25	In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe. Scientific Reports, 2016, 6, 23314.	3.3	36
26	Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level. Journal of Hematology and Oncology, 2016, 9, 56.	17.0	97
27	A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. Oncotarget, 2015, 6, 21533-21546.	1.8	76
28	Computational design of novel peptidomimetic inhibitors of cadherin homophilic interactions. Organic and Biomolecular Chemistry, 2015, 13, 2570-2573.	2.8	16
29	Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen. Immunology Letters, 2015, 168, 105-110.	2.5	11
30	Targeting FR-expressing cells in ovarian cancer with Fab-functionalized nanoparticles: a full study to provide the proof of principle from in vitro to in vivo. Nanoscale, 2015, 7, 2336-2351.	5.6	27
31	Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. Oncotarget, 2015, 6, 28911-28928.	1.8	45
32	PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models. PLoS ONE, 2014, 9, e109427.	2.5	64
33	Introductory Remarks for the Diagnostic and Therapeutic Applications of Monoclonal Antibodies and Various Formats. , 2014, , 83-90.		0
34	Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. Future Oncology, 2013, 9, 527-539.	2.4	35
35	A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. European Journal of Cancer, 2013, 49, 2223-2232.	2.8	47
36	CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood, 2012, 119, 696-706.	1.4	296

#	Article	IF	Citations
37	Broad-Spectrum Inhibition of HIV-1 by a Monoclonal Antibody Directed against a gp120-Induced Epitope of CD4. PLoS ONE, 2011, 6, e22081.	2.5	6
38	Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcÉ›RIâ€mediated basophil activation by a tumourâ€specific IgE antibody to evaluate the risk of type I hypersensitivity. Clinical and Experimental Allergy, 2011, 41, 1400-1413.	2.9	38
39	Antitumor Effects of a Human Dimeric Antibody Fragment ¹³¹I-AFRA-DFM5.3 in a Mouse Model for Ovarian Cancer. Journal of Nuclear Medicine, 2011, 52, 1938-1946.	5.0	14
40	In VivoPersistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB). Cancer Research, 2011, 71, 4617-4627.	0.9	256
41	Anti-FR Antibody Generation and Engineering: Development of New Therapeutic Tools. , 2011, , 151-179.		0
42	Shed HER2 extracellular domain in HER2â€mediated tumor growth and in trastuzumab susceptibility. Journal of Cellular Physiology, 2010, 225, 256-265.	4.1	28
43	Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor. Cancer Immunology, Immunotherapy, 2009, 58, 531-546.	4.2	23
44	177Lu- labeled MOv18 as compared to 131I- or 90Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts. Nuclear Medicine and Biology, 2009, 36, 759-770.	0.6	26
45	Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection. Journal of Translational Medicine, 2009, 7, 101.	4.4	5
46	Dissecting the Structural Determinants of the Interaction between the Human Cytomegalovirus UL18 Protein and the CD85j Immune Receptor. Journal of Immunology, 2008, 180, 957-968.	0.8	10
47	Activation of the Osteopontin/Matrix Metalloproteinase-9 Pathway Correlates with Prostate Cancer Progression. Clinical Cancer Research, 2008, 14, 7470-7480.	7.0	99
48	Redirected Activity of Human Antitumor Chimeric Immune Receptors is Governed by Antigen and Receptor Expression Levels and Affinity of Interaction. Journal of Immunotherapy, 2007, 30, 684-693.	2.4	70
49	Complement Activated by Chimeric Antiâ€"Folate Receptor Antibodies Is an Efficient Effector System to Control Ovarian Carcinoma. Cancer Research, 2006, 66, 3876-3883.	0.9	36
50	The Use of a Tropism-Modified Measles Virus in Folate Receptorâ€"Targeted Virotherapy of Ovarian Cancer. Clinical Cancer Research, 2006, 12, 6170-6178.	7.0	87
51	775. Folate Receptor Targeted Virotherapy of Ovarian Cancer Using a Tropism Modified Measles Virus. Molecular Therapy, 2006, 13, S300.	8.2	0
52	Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor. Journal of Gene Medicine, 2005, 7, 158-170.	2.8	26
53	90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunology, Immunotherapy, 2005, 54, 1200-1213.	4.2	39
54	CD95-Mediated Apoptosis Is Impaired at Receptor Level by Cellular FLICE-Inhibitory Protein (Long Form) in Wild-Type p53 Human Ovarian Carcinoma. Clinical Cancer Research, 2004, 10, 5202-5214.	7.0	52

#	Article	IF	Citations
55	A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and -4 processing. Oncogene, 2004, 23, 7552-7560.	5.9	25
56	Isolation of Human Fab Fragments Against Ovarian Carcinoma Using Guided Selection. , 2003, 207, 145-160.		1
57	Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Therapy, 2003, 10, 1018-1025.	4.5	68
58	Isolation of Human Monoclonal Antibodies Using Guided Selection with Mouse Monoclonal Antibodies. , 2002, 178, 207-217.		2
59	Re: Blocking Oncogenic Ras Signaling for Cancer Therapy. Journal of the National Cancer Institute, 2002, 94, 1031-1032.	6.3	11
60	Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2. Cancer Immunology, Immunotherapy, 2001, 49, 679-686.	4.2	7
61	Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to Î±-folate receptor overexpression. Oncogene, 2000, 19, 4754-4763.	5.9	74
62	Single-step purification of immunotoxins containing a high ionic charge ribosome inactivating protein clavin by carboxymethyl high-performance membrane chromatography. Journal of Chromatography A, 1999, 830, 329-335.	3.7	6
63	Approaches to implement bispecific antibody treatment of ovarian carcinoma. Cancer Immunology, Immunotherapy, 1997, 45, 187-189.	4.2	6
64	New Techniques for the Production of Therapeutic Recombinant Human Monoclonal Antibodies. BioDrugs, 1995, 4, 301-311.	0.7	1
65	In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation. Journal of Molecular Biology, 1994, 239, 68-78.	4.2	76
66	Glycolipids carrying Ley are preferentially expressed on small-cell lung cancer cells as detected by the monoclonal antibody MLuC1. International Journal of Cancer, 1992, 51, 225-231.	5.1	18
67	Characterization of a mouse-human chimeric antibody to a cancer-associated antigen. International Journal of Cancer, 1992, 52, 588-593.	5.1	8